1-(1甲基-1H-吡唑-4-基)-环丙胺 | 1338494-61-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(1甲基-1H-吡唑-4-基)-环丙胺
• 英文名称: 1-(1-methyl-1H-pyrazol-4-yl)cyclopropanamine
• 英文别名: 1-(1-methyl-1H-pyrazol-4-yl)cyclopropan-1-amine；1-(1-methylpyrazol-4-yl)cyclopropan-1-amine
• CAS: 1338494-61-3
• 化学式: C₇H₁₁N₃
• mdl: MFCD20441460
• 分子量: 137.184
• InChiKey: OWJBIEVIQPWJFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1甲基-1H-吡唑-4-基)-环丙胺 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 6.88h， 生成 6-bromo-3-[1-(1-methyl-1H-pyrazol-4-yl)cyclopropyl]-1,2,3,4-tetrahydroquinazoline-2,4-dione
  参考文献：
  名称：

  [EN] INHIBITORS OF PARG
  [FR] INHIBITEURS DE PARG

  摘要：

  Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.

  公开号：

  WO2023224998A1
• 作为产物：
  描述：

  乙基溴化镁 、 1 -甲基- 1H-吡唑- 4 -腈 在 titanium(IV) isopropylate 、 三氟化硼乙醚 作用下， 以 四氢呋喃 为溶剂， 生成 1-(1甲基-1H-吡唑-4-基)-环丙胺
  参考文献：
  名称：

  INDOLE DERIVATIVES FOR USE IN MEDICINE

  摘要：

  提供一种色氨酸-2,3-双加氧酶（TDO）和/或吲哚胺-2,3-双加氧酶（IDO）抑制剂化合物，用于医学，该化合物包括以下式子：其中X1、X2、X3、X4和X5可以相同或不同，并且每个独立地选择自C、N和O；每个有点线的原子可以独立地具有双键或单键，前提是每个原子的价被保持；每个R1、R2、R3、R4和R7可以存在或不存在，可以相同或不同，并且选择自H和取代或未取代的有机基团，前提是存在的这些R基团的数量使得X1、X2、X3、X4和X5的价被保持；可以存在一或两个R6基团，选择自H和取代或未取代的有机基团，前提是存在的这些R6基团的数量使得它们附着的碳原子的价被保持，并且至少有一个R6是包含一个双键连接到α-、β-或γ-位置的氧原子（优选为羰基基团或磺酰基团）的有机基团，并且其中双键连接到氧原子的原子也与杂原子相结合。

  公开号：

  US20190084933A1

文献信息

• [EN] PHARMACEUTICAL COMPOUND<br/>[FR] COMPOSÉ PHARMACEUTIQUE
  申请人：IOMET PHARMA LTD

  公开号：WO2017048612A1

  公开（公告）日：2017-03-23

  Provided is a compound having formula (I): wherein R2 is selected from -C1, -Br and -CN; R1 and R4 are independently selected from H and -F; R631, R632, R641 and R642 are independently selected from -H, -F and substituted or unsubstituted C1-C3 alkyl groups; and R651 and R652 are independently selected from H and substituted or unsubstituted C1-C3 alkyl groups and substituted or unsubstituted phenyl groups; and wherein at least one of R631, R632, R641, R642 and R652 is not -H, or wherein when all of R631, R632, R641, R642 and R652 are -H, R651 is not Me or Et.

  提供的化合物的化学式为（I）：其中R2从-C1，-Br和-CN中选择；R1和R4可独立选择H和-F；R631、R632、R641和R642可独立选择-H，-F和取代或未取代的C1-C3烷基基团；R651和R652可独立选择H和取代或未取代的C1-C3烷基基团和取代或未取代的苯基；至少其中一个R631、R632、R641、R642和R652不是-H，或者当所有R631、R632、R641、R642和R652都是-H时，R651不是Me或Et。
• [EN] INDOLE DERIVATIVES FOR USE IN MEDICINE<br/>[FR] DÉRIVÉS INDOLÉS DESTINÉS À ÊTRE UTILISÉS DANS LE DOMAINE DE LA MÉDECINE
  申请人：IOMET PHARMA LTD

  公开号：WO2015150097A1

  公开（公告）日：2015-10-08

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, R5, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

  提供了一种色氨酸2,3-双加氧酶（TDO）和/或吲哚酮-2,3-双加氧酶（IDO）抑制剂化合物，用于医学，该化合物包括以下结构式：其中X1、X2、X3、X4和X5可以相同或不同，并且每个独立地选择自C、N和O；每个有点线的原子可以独立地具有双键或单键，前提是保持每个原子的价；每个R1、R2、R3、R4、R5和R7可以存在或不存在，并且可以相同或不同，并且选择自H和取代或未取代的有机基团，前提是存在这样的R基团的数量使得X1、X2、X3、X4和X5的价被保持；可以存在一个或两个R6基团，并且选择自H和取代或未取代的有机基团，前提是存在这样的R6基团的数量使得它们附着的碳原子的价被保持，并且前提是至少有一个R6是包含一个与氧原子双键的原子的有机基团（优选为一个羰基基团或一个磺酰基基团），在其中与氧原子双键的原子也与一个杂原子键合。
• Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10336731B2

  公开（公告）日：2019-07-02

  Provided is a compound having formula (I): wherein R2 is selected from —C1, —Br and —CN; R1 and R4 are independently selected from H and —F; R631, R632, R641 and R642 are independently selected from —H, —F and substituted or unsubstituted C1-C3 alkyl groups; and R651 and R652 are independently selected from H and substituted or unsubstituted C1-C3 alkyl groups and substituted or unsubstituted phenyl groups; and wherein at least one of R631, R632, R641, R642 and R652 is not —H, or wherein when all of R631, R632, R641, R642 and R652 are —H, R651 is not Me or Et.

  提供了一种具有式(I)的化合物：其中 R2 选自-C1、-Br 和-CN；R1 和 R4 独立选自 H 和-F；R631、R632、R641 和 R642 独立选自-H、-F 和取代或未取代的 C1-C3 烷基；以及 R651 和 R652 独立选自 H 和取代或未取代的 C1-C3 烷基以及取代或未取代的苯基；其中 R631、R632、R641、R642 和 R652 中至少有一个不是-H，或者当所有 R631、R632、R641、R642 和 R652 都是-H 时，R651 不是 Me 或 Et。
• Indole derivatives for use in medicine
  申请人：IOMet Pharma Ltd.

  公开号：US10858319B2

  公开（公告）日：2020-12-08

  Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom double-bonded to an oxygen atom (preferably a carbonyl group or a sulphonyl group) at an α-, β-, or γ-position to the carbon atom to which the R6 is attached and in which the atom double-bonded to an oxygen atom is also bonded to a hetero-atom.

  本发明提供了一种用于医药的色氨酸-2,3-二氧化酶（TDO）和/或吲哚胺-2,3-二氧化酶（IDO）抑制剂化合物，该化合物包括下式：其中 X1、X2、X3、X4 和 X5 可以相同或不同，且各自独立地选自 C、N 和 O；每个带有虚线的原子可以独立地具有双键或单键，前提是每个原子上的价保持不变；每个 R1、R2、R3、R4 和 R7 可以存在或不存在，可以相同或不同，并且选自 H 和取代或未取代的有机基团，条件是存在的此类 R 基团的数目使得 X1、X2、X3、X4 和 X5 的价得以保持；可存在一个或两个 R6 基团，它们选自 H 和一个取代或未取代的有机基团，条件是所存在的 R6 基团的数目必须保证它们所连接的碳原子的价保持不变、且至少有一个 R6 是有机基团，该有机基团包含一个与氧原子（最好是羰基或磺酰基）在与 R6 所连接的碳原子的 α-、β- 或 γ- 位置上双键结合的原子，其中与氧原子双键结合的原子还与杂原子结合。
• [EN] SUBSTITUTED ISOXAZOLINE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOXAZOLINE SUBSTITUÉS
  申请人：[en]BASF SE

  公开号：WO2022171472A1

  公开（公告）日：2022-08-18

  The invention relates to isoxazoline compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting growing plants and animals from attack or infestation by invertebrate pests, furthermore, to seed comprising such compounds.